CHRS - Coherus spikes after mid-stage data for liver cancer therapy
2024-01-19 07:29:39 ET
More on Coherus BioSciences
- Coherus BioSciences: FDA Approvals Spice Up The Pipeline
- Coherus BioSciences Is A Buy On The Dip After Toripalimib Approval
- Coherus: The Surface Acquisition Is A Distraction
- Coherus ends Junshi-partnered TIGIT Program in portfolio shakeup
- Coherus gets FDA approval for new Udenyca delivery system, stock +24% after hours
For further details see:
Coherus spikes after mid-stage data for liver cancer therapy